Zacks Research Issues Positive Forecast for Bruker Earnings

Bruker Co. (NASDAQ:BRKR) – Stock analysts at Zacks Research upped their FY2027 EPS estimates for shares of Bruker in a report issued on Tuesday, March 11th. Zacks Research analyst R. Department now forecasts that the medical research company will post earnings per share of $3.61 for the year, up from their prior estimate of $3.60. The consensus estimate for Bruker’s current full-year earnings is $2.69 per share.

Bruker (NASDAQ:BRKR) last posted its earnings results on Thursday, February 13th. The medical research company reported $0.76 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.75 by $0.01. Bruker had a net margin of 3.36% and a return on equity of 21.01%.

A number of other research firms have also recently issued reports on BRKR. Barclays cut their target price on shares of Bruker from $69.00 to $65.00 and set an “overweight” rating for the company in a research note on Monday, February 10th. Guggenheim restated a “buy” rating on shares of Bruker in a research note on Monday, February 24th. The Goldman Sachs Group upgraded shares of Bruker from a “sell” rating to a “neutral” rating and set a $60.00 price objective for the company in a research note on Thursday, December 5th. Stifel Nicolaus dropped their price objective on shares of Bruker from $70.00 to $57.00 and set a “hold” rating for the company in a research note on Friday, February 14th. Finally, UBS Group began coverage on shares of Bruker in a research note on Tuesday, December 10th. They issued a “neutral” rating and a $66.00 price objective for the company. Six investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $70.50.

Bruker Stock Performance

NASDAQ BRKR opened at $45.97 on Thursday. The firm has a 50-day moving average of $53.93 and a 200-day moving average of $58.57. The company has a debt-to-equity ratio of 1.15, a quick ratio of 0.77 and a current ratio of 1.60. The stock has a market cap of $6.97 billion, a PE ratio of 60.49, a P/E/G ratio of 2.16 and a beta of 1.18. Bruker has a 52-week low of $44.11 and a 52-week high of $94.86.

Bruker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Monday, March 17th will be issued a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a dividend yield of 0.44%. The ex-dividend date is Monday, March 17th. Bruker’s dividend payout ratio (DPR) is presently 26.32%.

Institutional Investors Weigh In On Bruker

Hedge funds and other institutional investors have recently made changes to their positions in the stock. True Wealth Design LLC grew its holdings in shares of Bruker by 4,636.4% during the 3rd quarter. True Wealth Design LLC now owns 521 shares of the medical research company’s stock valued at $36,000 after purchasing an additional 510 shares during the last quarter. Eagle Bay Advisors LLC grew its holdings in shares of Bruker by 2,324.1% during the 4th quarter. Eagle Bay Advisors LLC now owns 703 shares of the medical research company’s stock valued at $41,000 after purchasing an additional 674 shares during the last quarter. UMB Bank n.a. grew its holdings in shares of Bruker by 37.5% during the 4th quarter. UMB Bank n.a. now owns 909 shares of the medical research company’s stock valued at $53,000 after purchasing an additional 248 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of Bruker by 47.5% during the 4th quarter. GAMMA Investing LLC now owns 1,279 shares of the medical research company’s stock valued at $75,000 after purchasing an additional 412 shares during the last quarter. Finally, Quadrant Capital Group LLC grew its holdings in shares of Bruker by 18.2% during the 4th quarter. Quadrant Capital Group LLC now owns 1,273 shares of the medical research company’s stock valued at $75,000 after purchasing an additional 196 shares during the last quarter. 79.52% of the stock is owned by institutional investors.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.